Mitigation

TCP Software named 2024 SIIA CODiE Award Finalist in Best Compliance Solution and Best Administrative Solution categories

Retrieved on: 
Tuesday, April 9, 2024
Professional Services, Education, Data Management, Technology, Human Resources, Software, Other Education, Organization, Educational technology, SIIA, Mitigation, TCP, TimeClock Plus, Warehouse

TCP Software , a leading provider of time, attendance, and employee scheduling solutions, today announced that TimeClock Plus was named a 2024 SIIA CODiE Award Finalist in Best Compliance Solution and Best Administrative Solution categories.

Key Points: 
  • TCP Software , a leading provider of time, attendance, and employee scheduling solutions, today announced that TimeClock Plus was named a 2024 SIIA CODiE Award Finalist in Best Compliance Solution and Best Administrative Solution categories.
  • CODiE Finalists represent the best products, services, and people in the Education and Business Technology Industries.
  • TimeClock Plus was selected as a finalist among hundreds of nominations across dozens of Business Technology and Education Technology categories.
  • "We’re thrilled to be finalists in two categories that speak directly to the value TCP delivers to our customers,” says Daryl Rolley, CEO of TCP Software.

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Retrieved on: 
Monday, April 1, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Factor D, Arthralgia, Chest pain, Confusion, Neuropsychological test, Infection, Eculizumab, Risk, Headache, ALPHA, PNH, C5, Patient, Orphan, Mitigation, Vaccine, Light, Paroxysmal nocturnal hemoglobinuria, EVH, Bacteria, University, Chills, MD, Breakthrough therapy, Cough, European Medicines Agency, Fatigue, Nausea, Rash, Fever, Priority, Safety, Immune system, REMS, Division, Vomiting, Hematology, Patient safety, Medicine

VOYDEYA has also been granted Orphan Drug Designation in the US, European Union (EU) and Japan for the treatment of PNH.

Key Points: 
  • VOYDEYA has also been granted Orphan Drug Designation in the US, European Union (EU) and Japan for the treatment of PNH.
  • You must complete or update meningococcal vaccine(s) and streptococcus vaccine(s) at least 2 weeks before your first dose of VOYDEYA.
  • If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting VOYDEYA.
  • Carry it with you at all times during treatment and for 1 week after your last VOYDEYA dose.

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio

Retrieved on: 
Monday, March 25, 2024
Health, Clinical Trials, General Health, Pharmaceutical, Cardiology, Biotechnology, BMY, Patient, Mitigation, Bristol Myers Squibb, MD, Senior, LVEF, American College, Safety, REMS, ACC, Risk, Hospital, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place April 6-8, 2024 in Atlanta, Georgia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place April 6-8, 2024 in Atlanta, Georgia.
  • These data are consistent with the clinical development program and reinforce the safety profile of CAMZYOS in clinical practice.
  • This effectiveness and safety information about ELIQUIS use in clinical practice can supplement data from randomized clinical trials.
  • Visit this page on BMS.com for more information on Bristol Myers Squibb’s scientific approach and resources on cardiovascular diseases.

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

Retrieved on: 
Friday, March 22, 2024
Diagnosis, ESC, Toxicity, ERA, Tadalafil, Internal medicine, European Respiratory Society, Disease, Risk, Pulmonary hypertension, Patient, PVR, Mitigation, Female, Nitric oxide, Connective tissue disease, Orthostatic hypertension, World Health Organization, PDE5, Johnson & Johnson, REMS, WHO, Pulmonary circulation, PAH, FDA, Constriction, ERS, Food, Pharmaceutical industry

RARITAN, N.J., March 22, 2024  /PRNewswire/ -- Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI® – a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor – for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group I) and WHO functional class (FC) II-III.1 OPSYNVI® may be used in patients with PAH who are treatment-naïve or who are already on an ERA, PDE5 inhibitor or both. OPSYNVI® may be used in patients who are currently treated concomitantly with stable doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets.1

Key Points: 
  • Historically, this required patients to take multiple pills because no single-tablet combination therapy targeting two or more pathways was available," said Kelly Chin, M.D., Professor of Internal Medicine and Director of the Pulmonary Hypertension Program at UT Southwestern Medical Center, and an investigator in the A DUE study.
  • The FDA's approval of OPSYNVI® is based on the results from the pivotal Phase 3 A DUE study , in which OPSYNVI® demonstrated greater reduction in Pulmonary Vascular Resistance (PVR) after 16 weeks versus tadalafil or macitentan monotherapy.
  • "People with PAH often live with the burden of taking many pills each day, which can pose challenges," said James F. List, M.D., Ph.D., Global Therapeutic Area Head, whose team oversees a portfolio of programs including Pulmonary Hypertension at Johnson & Johnson.
  • "We're thrilled to bring this single-tablet combination therapy to patients, as it has the potential to optimize disease management and fulfill a significant unmet need in supporting recently updated treatment guidelines that call for initial or early combination treatment."

Sandoz receives FDA approval for first and only denosumab biosimilars

Retrieved on: 
Tuesday, March 5, 2024
Bone fracture, Fracture, Woman, Hypocalcemia, Osteoporosis, Bone disease, Hypercalcaemia, FDA, Quality of life, Food, Cancer, Denosumab, Metastasis, Risk, Breast, Safety, Mitigation, Novartis, REMS, Benign tumor, Disease, Patent, Patient, Medicine, Multiple myeloma, Ageing, Dietary supplement

Keren Haruvi, President Sandoz North America, said: "Sandoz has achieved the first FDA approval for biosimilars to denosumab, a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events, which are disease states that can profoundly reduce quality of life for patients.

Key Points: 
  • Keren Haruvi, President Sandoz North America, said: "Sandoz has achieved the first FDA approval for biosimilars to denosumab, a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events, which are disease states that can profoundly reduce quality of life for patients.
  • I am proud that Sandoz continues to pioneer access to these life-changing medicines for the patients who need them most."
  • Wyost® and Jubbonti® have the same dosage form, route of administration, dosing regimen and presentation as the respective reference medicines.
  • Given ongoing patent litigation around these products, Sandoz will not comment on anticipated launch timing or other launch details at this time.

Cloudflare Expands Capabilities to Protect Organizations Against Emerging Threats with Defensive AI

Retrieved on: 
Monday, March 4, 2024
Software, Networks, Internet, Data Management, Technology, Apps, Applications, Mobile, Wireless, Security, Cloud, AI, Generative, Mitigation, Risk, Behavior, Zero trust security model, Synthetic media, Organization, Environment, Medical device

Cloudflare, Inc. (NYSE: NET), the leading connectivity cloud company, today announced Defensive AI, a personalized approach to securing organizations against the new wave of risks presented by emerging technology.

Key Points: 
  • Cloudflare, Inc. (NYSE: NET), the leading connectivity cloud company, today announced Defensive AI, a personalized approach to securing organizations against the new wave of risks presented by emerging technology.
  • The crown jewels and trade secrets of organizations vary, and to protect them, organizations require highly agile security strategies.
  • While AI holds tremendous potential for organizations, it also allows threat actors to rapidly increase their effectiveness and renders one-size-fits-all security offerings obsolete.
  • As emerging technology evolves and new tools are developed, Cloudflare is positioned to allow organizations to embrace these productivity enhancements without exposing themselves to malicious use cases.

Travelers Institute Launches 2024 National Cybersecurity Tour

Retrieved on: 
Monday, February 26, 2024
Professional Services, Business, Security, Technology, Small Business, Insurance, Public policy, Traveler, CISA, Assistant, Mitigation, Computer security, Information system, The Travelers Companies, TRV, Organization, SBA

The Travelers Institute , the public policy division of The Travelers Companies, Inc. (NYSE: TRV ), today announced the start of its Cyber: Prepare, Prevent, Mitigate, Restore® 2024 tour schedule.

Key Points: 
  • The Travelers Institute , the public policy division of The Travelers Companies, Inc. (NYSE: TRV ), today announced the start of its Cyber: Prepare, Prevent, Mitigate, Restore® 2024 tour schedule.
  • The overwhelming majority of respondents (81%) believe that having proper cybersecurity controls in place is critical to the well-being of their company.
  • “Cyber risks can cause major operational and financial disruption to an organization, which is why it’s important for businesses – particularly small enterprises – to take preventive measures,” said Joan Woodward, President of the Travelers Institute and Executive Vice President of Public Policy at Travelers.
  • The SBA has made it a priority to help business owners understand the importance of cybersecurity and ways they can safeguard their customers’ data.”
    Travelers Institute programs are free and open to the public.

Spring 2024 CFO Leadership Conference: Driving Business Transformation: Spotlight on Spring 2024 CFO Leadership Conference Breakout sessions

Retrieved on: 
Tuesday, February 20, 2024
CFO, Senior, Mitigation, Growth, SPHR, Business development, Conference, CFOS, Finance, SHRM, Management

BOSTON, Feb. 20, 2024 /PRNewswire-PRWeb/ -- The CFO Leadership Council (CFOLC), a premier association for senior finance leaders committed to advancing their careers and driving business growth, is thrilled to introduce the latest additions to our distinguished lineup of breakout sessions.

Key Points: 
  • CFOLC's Spring 2024 Conference in Boston, MA announces Dynamic breakout sessions including "Future-Proof Compliance" and "HR Partnership for Profit."
  • BOSTON, Feb. 20, 2024 /PRNewswire-PRWeb/ -- The CFO Leadership Council (CFOLC), a premier association for senior finance leaders committed to advancing their careers and driving business growth, is thrilled to introduce the latest additions to our distinguished lineup of breakout sessions.
  • "Unlocking Global Growth and Financial Stability: Dive into Breakout Sessions at the Spring 2024 CFO Leadership Conference!"
  • Immerse yourself in the Spring 2024 CFO Leadership Conference, where over 300 senior financial leaders from diverse industries convene for a vibrant exchange of insights and strategies amidst today's complex business landscape.

DataDome Expands Bot Bounty Program to the Public, Invites Researchers to Rigorously Test its Solution

Retrieved on: 
Tuesday, February 13, 2024
G2, News, YesWeHack, Mitigation, API, Application, Denial-of-service attack, Application security, Partnership

NEW YORK, Feb. 13, 2024 /PRNewswire/ -- DataDome, a leading provider of AI-powered online fraud and bot management, today announced it has opened its bot bounty program to the public, in partnership with ethical hacking platform YesWeHack. This initiative incentivizes an extended community of external researchers to rigorously test DataDome's protection, in order to identify any potential vulnerabilities.

Key Points: 
  • This initiative incentivizes an extended community of external researchers to rigorously test DataDome's protection, in order to identify any potential vulnerabilities.
  • In this technical challenge, participants are encouraged to implement a scraping bot to scrape as much content as possible from two dedicated websites without being blocked by DataDome's solution.
  • Initially launched as a private bot bounty program in 2018, the internet's best bot builders have tried their hand at breaking DataDome's bot defenses, with 80,000+ monthly attempts.
  • Security researchers and enthusiasts interested in participating in the bot bounty program can find detailed information, guidelines, and submission instructions on YesWeHack's site .

UN Global Compact launches Transformational Governance Corporate Toolkit

Retrieved on: 
Tuesday, February 13, 2024
Investment, Biophysical environment, Mitigation, ESG, United Nations Global Compact, Benefit, SDG, Organization, Policy, Role, Society, Justice

New York, United States of America, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The UN Global Compact, the world's largest corporate sustainability initiative, announced today the launch of its Transformational Governance Corporate Toolkit .

Key Points: 
  • New York, United States of America, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The UN Global Compact, the world's largest corporate sustainability initiative, announced today the launch of its Transformational Governance Corporate Toolkit .
  • Sanda Ojiambo, CEO and Executive Director of the UN Global Compact, emphasizes the importance of this toolkit for business: "The Transformational Governance Corporate Toolkit is a milestone in our ongoing efforts to equip companies with the tools they need to advance sustainable and responsible business practices.
  • The toolkit includes a user-friendly online Transformational Governance Self-Assessment Tool , providing a framework for companies to engage with and apply the principles of transformational governance.
  • The toolkit was developed in collaboration with participating companies and partner organizations of the United Nations Global Compact Think Lab on Transformational Governance .